Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma—a phase II trial of the AIO study group (AIO STO 0321)

Overview of attention for article published in Frontiers in oncology, October 2023

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 2 Dimensions

Readers on

mendeley: 3 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 18,713 followers.

RT @FrontOncology: New research: Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, lo…

18 Oct 2023

Reply Repost Favourite

New research: Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma—a phase II trial of the AIO study group (AIO STO 0321): Background Esophagogastric… https://t.co

18 Oct 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.